Intratumoral Cancer Therapies Global Market Report 2025

Description

Intratumoral cancer therapies involve treatments directly administered or applied to a tumor. These therapies are specifically crafted to target tumor cells and can be employed in conjunction with other cancer treatments, such as chemotherapy and radiation therapy.

The primary categories of intratumoral cancer therapies encompass monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies denote a specific type of artificially created protein capable of binding to particular bodily targets, including antigens present on the surface of cancer cells. They find application in various contexts, such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, among others, and are utilized by diverse end users, including hospitals, cancer research centers, and clinics.

The intratumoral cancer therapies market research report is one of a series of new reports from The Business Research Company that provides intratumoral cancer therapies market statistics, including intratumoral cancer therapies industry global market size, regional shares, competitors with an intratumoral cancer therapies market share, detailed intratumoral cancer therapies market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. This intratumoral cancer therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $140 billion in 2024 to $158.38 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to advancements in cancer research, increasing cancer incidence, demand for precision medicine, clinical evidence and research initiatives, unmet medical needs.

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $248.42 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advancements in immunotherapy, increased adoption of precision medicine, clinical trial expansion, rising focus on rare cancers, regulatory support and approvals. Major trends in the forecast period include exploration of intratumoral immunomodulators, integration of image-guided therapies, application of hyperthermia in intratumoral treatments, clinical trials for combination therapies, regulatory support for intratumoral therapies.

The rising incidence of cancer is anticipated to drive the growth of the intratumoral cancer therapies market in the future. Cancer refers to a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells within the body. Intratumoral cancer therapies are utilized in the diagnosis and treatment of cancer, helping to mitigate off-target toxicities, dose-limiting toxicities, and adverse effects associated with immune stimulation in patients with cancer. For example, in January 2023, the American Cancer Society, a US-based nonprofit organization dedicated to cancer advocacy, reported that the number of cancer cases reached 1,958,310 in 2023, marking a 3.16% increase from 1,898,160 in 2021. Thus, the rising incidence of cancer is fueling the growth of the intratumoral cancer therapies market.

The increasing integration of immunotherapy is expected to further accelerate the growth of the intratumoral cancer therapies market in the coming years. Immunotherapy is a type of cancer treatment that utilizes substances produced by the body or created in a laboratory to enhance the immune system and assist the body in locating and destroying cancer cells. Intratumoral therapies align with the growing emphasis on immunotherapy, offering a localized and effective approach to modulating the immune response within the tumor microenvironment. For instance, in June 2022, the United States Food and Drug Administration (FDA), a federal agency of the US Department of Health and Human Services, approved 35 immune checkpoint inhibitor (ICI)-based combination immunotherapies in 2022. Consequently, the rise in immunotherapy integration is driving the growth of the intratumoral cancer therapies market.

Technological advancements emerge as a noteworthy trend in the intratumoral cancer therapies market. Companies in this sector are adopting innovative technologies to maintain their market standing. For instance, in March 2022, Evonik, a US-based specialty chemical manufacturing company, introduced EUDRATEC SoluFlow, a novel microparticle technology designed to enhance the solubility of active medicinal components in oral cancer medication formulations. This breakthrough technology allows previously considered insoluble chemicals to be used in a broader range of oral medications.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, partnered with Pfizer Inc. to leverage artificial intelligence (AI) for drug discovery and development. Through this collaboration, Pfizer will incorporate CytoReason's AI technologies into its drug research activities, with the agreement valued up to $110 million over the next five years. Pfizer's contribution includes $20 million in stock, options to license CytoReason's platform and disease models, and additional project support. Pfizer Inc., a US-based pharmaceutical company specializing in intestine cancer therapeutics, aims to enhance its drug discovery efforts through this collaboration.

In January 2023, AstraZeneca, a UK-based biopharmaceutical company focused on the research, commercialization, and discovery of prescription medications for oncology and rare diseases, acquired Neogene Therapeutics Inc. for $120 million. This acquisition will create new opportunities for AstraZeneca in the field of cancer treatment. Neogene Therapeutics Inc. is a Netherlands-based biotechnology research firm that provides personalized therapies based on TCR genes that specifically target neoantigens found in a patient's tumor.

Major companies operating in the intratumoral cancer therapies market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Regeneus Ltd., QBiotics Group, VetDC

North America was the largest region in the intratumoral cancer therapies market in 2024. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the intratumoral cancer therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intratumoral cancer therapies market consists of revenues earned by entities by chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intratumoral Cancer Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intratumoral cancer therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intratumoral cancer therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intratumoral cancer therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Technology: Monoclonal Antibodies; Vaccines; Checkpoint Inhibitors; Cell Therapies; Immunes System Modulator; Adoptive Cell Transfer; Cytokines
2) By Application: Lung Cancer; Breast Cancer; Melanoma; Prostate Cancer; Head And Neck Cancer; Other Applications
3) By End Users: Hospitals; Cancer Research Centers; Clinics
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
2) By Vaccines: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors
4) By Cell Therapies: CAR T-Cell Therapy; TCR Therapy
5) By Immune System Modulators: Immune Checkpoint Inhibitors; Toll-Like Receptor Agonists
6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs); Peripheral Blood Lymphocytes (PBLs)
7) By Cytokines: Interleukins; Interferons; Tumor Necrosis Factor (TNF)
Companies Mentioned: Amgen Inc.; AstraZeneca plc; Bayer AG; Bristol-Myers Squibb Company; Pfizer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23489

1. Executive Summary

2. Intratumoral Cancer Therapies Market Characteristics

3. Intratumoral Cancer Therapies Market Trends And Strategies

4. Intratumoral Cancer Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Intratumoral Cancer Therapies Growth Analysis And Strategic Analysis Framework

5.1. Global Intratumoral Cancer Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Intratumoral Cancer Therapies Market Growth Rate Analysis
5.4. Global Intratumoral Cancer Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Intratumoral Cancer Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Intratumoral Cancer Therapies Total Addressable Market (TAM)

6. Intratumoral Cancer Therapies Market Segmentation

6.1. Global Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Vaccines
Checkpoint Inhibitors
Cell Therapies
Immune System Modulator
Adoptive Cell Transfer
Cytokines
6.2. Global Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lung Cancer
Breast Cancer
Melanoma
Prostate Cancer
Head And Neck Cancer
Other Applications
6.3. Global Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Research Centers
Clinics
6.4. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Naked Monoclonal Antibodies
Conjugated Monoclonal Antibodies
Bispecific Monoclonal Antibodies
6.5. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
6.6. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
PD-1 Or PD-L1 Inhibitors
CTLA-4 Inhibitors
6.7. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CAR T-Cell Therapy
TCR Therapy
6.8. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Immune System Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Toll-Like Receptor Agonists
6.9. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Adoptive Cell Transfer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor-Infiltrating Lymphocytes (TILs)
Peripheral Blood Lymphocytes (PBLs)
6.10. Global Intratumoral Cancer Therapies Market, Sub-Segmentation Of Cytokines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukins
Interferons
Tumor Necrosis Factor (TNF)

7. Intratumoral Cancer Therapies Market Regional And Country Analysis

7.1. Global Intratumoral Cancer Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Intratumoral Cancer Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intratumoral Cancer Therapies Market

8.1. Asia-Pacific Intratumoral Cancer Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intratumoral Cancer Therapies Market

9.1. China Intratumoral Cancer Therapies Market Overview
9.2. China Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intratumoral Cancer Therapies Market

10.1. India Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intratumoral Cancer Therapies Market

11.1. Japan Intratumoral Cancer Therapies Market Overview
11.2. Japan Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intratumoral Cancer Therapies Market

12.1. Australia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intratumoral Cancer Therapies Market

13.1. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intratumoral Cancer Therapies Market

14.1. South Korea Intratumoral Cancer Therapies Market Overview
14.2. South Korea Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intratumoral Cancer Therapies Market

15.1. Western Europe Intratumoral Cancer Therapies Market Overview
15.2. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intratumoral Cancer Therapies Market

16.1. UK Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intratumoral Cancer Therapies Market

17.1. Germany Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intratumoral Cancer Therapies Market

18.1. France Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intratumoral Cancer Therapies Market

19.1. Italy Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intratumoral Cancer Therapies Market

20.1. Spain Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intratumoral Cancer Therapies Market

21.1. Eastern Europe Intratumoral Cancer Therapies Market Overview
21.2. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intratumoral Cancer Therapies Market

22.1. Russia Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intratumoral Cancer Therapies Market

23.1. North America Intratumoral Cancer Therapies Market Overview
23.2. North America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intratumoral Cancer Therapies Market

24.1. USA Intratumoral Cancer Therapies Market Overview
24.2. USA Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intratumoral Cancer Therapies Market

25.1. Canada Intratumoral Cancer Therapies Market Overview
25.2. Canada Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intratumoral Cancer Therapies Market

26.1. South America Intratumoral Cancer Therapies Market Overview
26.2. South America Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intratumoral Cancer Therapies Market

27.1. Brazil Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intratumoral Cancer Therapies Market

28.1. Middle East Intratumoral Cancer Therapies Market Overview
28.2. Middle East Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intratumoral Cancer Therapies Market

29.1. Africa Intratumoral Cancer Therapies Market Overview
29.2. Africa Intratumoral Cancer Therapies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Intratumoral Cancer Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Intratumoral Cancer Therapies Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intratumoral Cancer Therapies Market Competitive Landscape And Company Profiles

30.1. Intratumoral Cancer Therapies Market Competitive Landscape
30.2. Intratumoral Cancer Therapies Market Company Profiles
- 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Intratumoral Cancer Therapies Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Johnson & Johnson
31.3. Eli Lilly and Company
31.4. F. Hoffmann-la Roche
31.5. Takeda Pharmaceutical Company Ltd.
31.6. GSK plc
31.7. Ziopharm Oncology Inc.
31.8. Celldex Therapeutics Inc.
31.9. Astellas Pharma Inc.
31.10. Sirnaomics
31.11. Checkmate Pharmaceuticals Inc.
31.12. Immunovative Therapies Ltd.
31.13. Idera Pharmaceuticals Inc.
31.14. Daiichi Sankyo
31.15. Philogen S.p.A.

32. Global Intratumoral Cancer Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intratumoral Cancer Therapies Market

34. Recent Developments In The Intratumoral Cancer Therapies Market

35. Intratumoral Cancer Therapies Market High Potential Countries, Segments and Strategies

35.1 Intratumoral Cancer Therapies Market In 2029 - Countries Offering Most New Opportunities
35.2 Intratumoral Cancer Therapies Market In 2029 - Segments Offering Most New Opportunities
35.3 Intratumoral Cancer Therapies Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer